Corbus Pharmaceuticals Bolsa (NASDAQ: CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa, Quote.MetaTitle.unusual-options

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Compugen

Caribou Biosciences

Cypherpunk Technologies Inc. - Common Stock

Cypherpunk Technologies

Forte Biosciences

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Genfit

Genelux

Heron Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nuvectis Pharma

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Exagen

Corbus Pharmaceuticals (CRBP) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Comments

Corbus Pharmaceuticals Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL